Prior to the developments of a Covid vaccine, and upon outstanding Phase III results for Nanoflu (which met every single end point and beat the industry leading vaccine) Nvax reached the market cap which it has today.
However, Nvax now has approvals for its Covid vaccine, is in the lead in developments of a combined flu and Covid vaccine, and has a good deal more cash in hand than it did in early 2020 when Nanoflu results were released.
This is an incredibly strong buy no matter how you slice it.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- setia100·2022-12-01A syringe too far to compete with the big brothers❗Have to settle for a bronze medal ❗😁🤝1Report
- 88wlam88·2022-11-30pharmaceutical makes ton of money in pandemic eraLikeReport
- Nglt23·2022-11-30Thks for sharingLikeReport
- JaiVenky·2022-12-01nice1Report
- LWayne·2022-12-01ok1Report
- csyen·2022-11-30OkLikeReport
- FrankieTok·2022-11-30okLikeReport
- alod·2022-11-30goodLikeReport
- Boein3G·2022-11-30giodLikeReport
- Dollarvan·2022-11-30KLikeReport
- neosg·2022-11-30okLikeReport
- llwoo·2022-11-30👌🏻LikeReport
- TANG413·2022-11-30okay ....LikeReport
- joshuanoob·2022-11-30okLikeReport
- Rusty11·2022-11-30niceLikeReport
- RKT·2022-11-30👍LikeReport
- qazwsxedcrfv·2022-11-30[Like]LikeReport
- Yao84·2022-11-30OkokLikeReport
- Linglong8191·2022-11-30Like plsLikeReport
- SalTheFun·2022-11-30YeahLikeReport